-0.16 | -3.48%
| Price and Volume | |
|---|---|
| Recent Price | 4.60 |
| 52 Week High | 6.70 |
| 52 Week Low | 2.36 |
| Avg. Daily Vol. (Mil) | 0.26 |
| Beta (3 year) | 1.96 |
| Share Related Items | |
| Mkt Cap (Mil) | 241.90 |
| Shares Out (Mil) | 52.59 |
| Float (Mil) | 50.56 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 14.00 |
| Current Ratio | 14.60 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 21.29 |
| Price/Book | 3.25 |
| Price/Cash Flow | -7.70 |
| Per Share Data | |
| Earnings | -0.64 |
| Sales | 0.22 |
| Book Value | 1.41 |
| Cash Flow | -0.59 |
| Business Summary | |
|---|---|
| Sangamo BioSciences, Inc is engaged in the research, development and commercialization of novel transcription factors for gene regulation and gene modification. | |
| General Information | |
| 501 Canal Boulevard
Richmond, CA 94804 |
|
| www.sangamo.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 84 | |
| CEO: Edward O. Lanphier,II | |
| Short Interest | |
| Current Month (Mil) | 4.59 |
| Previous Month (Mil) | 4.51 |
| Short Interest Ratio (Days) | 23.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -37.00 |
| Return on Investments | -45.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,315.04 | 2,837.36 | 16.25 |
Oil *
103.20
|
|
DOWN
160.83 |
DOWN
17.38 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.89
|
|
-1.28%
|
-1.30%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |
Connect with TheStreet